Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label long-term safety study of HS-10380 in adults with schizophrenia in China
CTR20262961Phase 3Active
- Sponsor
- 江苏豪森药业集团有限公司；上海翰森生物医药科技有限公司/ 江苏豪森药业集团有限公司
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of obuprazine in schizophrenia, sponsored by 江苏豪森药业集团有限公司；上海翰森生物医药科技有限公司/ 江苏豪森药业集团有限公司. Started Sep 2026; status: active.
02
Drugs
obuprazine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on CTR20262961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262961.